Sawbridgeworth, United Kingdom

Catherine Simone V Frydrych

This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Allergan, Inc.. Active years: 2016-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catherine Simone V Frydrych. Retrieved from https://idiyas.com/inventor/catherine-simone-v-frydrych

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: **Catherine Simone V Frydrych: Pioneering Innovations in Cyclosporin Research**

Introduction

Catherine Simone V Frydrych is an accomplished inventor based in Sawbridgeworth, GB, with a remarkable portfolio of three patents. Her work primarily focuses on the modification of cyclosporins, which have significant implications in the treatment of various medical conditions. Through her innovative approach, Frydrych has contributed to advancements in pharmaceutical compositions that can enhance patient care.

Latest Patents

Among her latest innovations, Catherine Frydrych has developed a notable patent titled **"Cyclosporins modified on the MeBmt sidechain by heterocyclic rings."** This invention relates to the creation of novel cyclosporin analogs and their respective processes for preparation. These analogs are essential for pharmaceutical compositions designed to address medical conditions, particularly ocular issues like dry eye.

Another significant patent includes **"Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized."** This invention showcases cyclosporin analogs that serve as potent inhibitors of cyclophilin D while demonstrating low immunosuppressive activity. The associated processes and pharmaceutical compositions provide valuable methods for treating conditions such as ischemia-reperfusion injury, including damage to myocardial and cerebral tissues, as well as ocular or retinal injuries.

Career Highlights

Catherine is currently employed by Allergan, Inc., a company recognized for its commitment to developing solutions that enhance the quality of life for patients. Her expertise and innovations are vital assets to the organization, fostering advancements in therapeutic treatments through her research.

Collaborations

Throughout her career, Catherine has collaborated with esteemed colleagues, including Simon Neil Pettit and Andrew D Jones. These partnerships reflect a shared commitment to innovation and the pursuit of excellence in research and development.

Conclusion

Catherine Simone V Frydrych stands as a testament to the impact that innovative thinking and scientific research can have on the medical field. With her focus on cyclosporin analogs and their applications, she continues to shape the future of pharmacology and patient care. Her contributions underscore the vital role inventors play in addressing medical challenges and improving therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…